The platform centers on the BloodAge report, an AI-generated analysis derived from routine blood work that identifies how quickly a patient is aging relative to their chronological age. By shifting the clinical focus from symptomatic treatment to biological age management, Accrua offers tailored regimens including hormone replacement therapy, testosterone support, and weight-loss medications like GLP-1 agonists. Progress is tracked via quarterly re-testing, creating a data-backed feedback loop for both patients and clinicians.

Deep Longevity’s entry into the U.S. market follows a successful peer-reviewed study published in Aging and Disease, which linked biological age gaps to significant mortality risks. The company aims to capture a share of the rapidly expanding digital health sector by utilizing an asset-light model. By partnering with existing telehealth infrastructure and independent physician networks, the firm avoids the heavy overhead of physical clinics or inventory management. This scalability allows for a national rollout immediately upon launch, supported by a subscription-based revenue stream that the Board views as a critical long-term growth engine for the group.